Cidara Therapeutics Announces Positive Topline Results From Its Phase 2B Navigate Trial
June 23 (Reuters) - Cidara Therapeutics Inc CDTX.O:
CIDARA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B NAVIGATE TRIAL EVALUATING CD388, A NON-VACCINE PREVENTATIVE OF SEASONAL INFLUENZA
CIDARA THERAPEUTICS INC - STUDY MEETS PRIMARY AND SECONDARY EFFICACY ENDPOINTS
CIDARA THERAPEUTICS INC - CD388 DOSES SHOW 76%, 61%, AND 58% PROTECTION FROM INFLUENZA
CIDARA THERAPEUTICS INC - CD388 WELL-TOLERATED WITH NO SAFETY SIGNALS OBSERVED
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

MSTR Stock Price Prediction 2026-2030: Is Strategy the Ultimate Bitcoin Leveraged Play?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Tradingkey







